Navigation Links
PharmAthene Presents Update on SparVax™ rPA Anthrax Vaccine Program at the 2012 World Vaccine Congress
Date:4/12/2012

ANNAPOLIS, Md., April 12, 2011 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP) announced today that Dr. Thomas Fuerst, Executive Vice President and Chief Scientific Officer, presented a comprehensive update on the Company's novel SparVax™ rPA anthrax vaccine program at the 2012 World Vaccine Congress, held at the Gaylord National Convention Center in Washington, DC, April 11-14, 2012.

SparVax™ is being developed to meet the government's need for an improved second generation anthrax vaccine that is safe, convenient, more cost-effective, and capable of providing rapid manufacturing scale-up in response to a national security emergency. 

New data based on a recent analysis of previous human clinical trial immunogenicity data and non-clinical animal study results for SparVax™ suggested a preliminary estimate of efficacy in humans of over 90% protection and nearly 100% protection based on a 6- and 12-month booster dose, respectively.  This analysis is based on a correlate of protection established under the Animal Rule in accordance with FDA guidelines. 

"The benefits of rPA-based anthrax vaccines are well established and we believe our program is at the forefront of efforts in this field," remarked Dr. Fuerst.  "We are very excited about the progress we continue to make in our SparVax™ program.  Beyond our clinical successes, a key differentiator is our robust manufacturing process, which enables production of a highly characterized, highly purified and stable vaccine in sufficient scale required to meet the government's mandate for a modern, second-generation rPA-based anthrax vaccine.  We look forward to commencing additional Phase II clinical testing of SparVax™ later this year and to continuing a very productive collaboration with our partners in government to address this important national
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. PharmAthene Secures $7.5 Million Credit Facility From GE Capital, Healthcare Financial Services
2. PharmAthene to Present at the 24th Annual ROTH Conference on Monday, March 12, 2012
3. PharmAthene to Present at the Noble Financial Eighth Annual Equity Conference on Tuesday, January 17, 2012
4. PharmAthene Reports Third Quarter 2011 Financial and Operating Results
5. PharmAthene Progresses Second Generation rPA Anthrax Vaccine
6. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
7. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
8. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
9. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
10. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
11. PharmAthene Completes $6.5 Million Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, ... announce the relaunch of his highly informative blog, now named ... “ What are Stem Cells ?” Dr. Harman’s purpose ... in the basics of stem cell therapy so that pet ... of treatment when considering regenerative medicine. , A veterinarian by ...
(Date:7/10/2014)... Montreal, QC (PRWEB) July 10, 2014 ... comfort and convenience. This rejuvenating device now comes with a ... that develops over time. , The new cup is thinner ... This design works to target rough, thin and uneven surfaces ... original firm cup for a stimulating treatment on areas such ...
(Date:7/10/2014)... , July 10, 2014  Franciscan St. ... of capnography for respiratory monitoring outside the ... healthcare leaders in embracing state-of-the-art patient safety ... patients are breathing and can alert medical ... measuring the amount of carbon dioxide the ...
(Date:7/10/2014)...  Kainos Capital, a firm specializing in acquiring and ... has acquired the Slim-Fast brand from Unilever. Unilever will ... the transaction were not disclosed. Slim-Fast is ... markets ready-to-drink shakes, powders, bars and snacks to retail ... in the United Kingdom and ...
Breaking Biology Technology:Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Kainos Capital Acquires Slim-Fast From Unilever 2
... N.C. , May 13 Chimerix, Inc., ... the commencement of a first-in-human study of CMX157, a ... in vitro activity against both tenofovir-sensitive and tenofovir-resistant ... increase efficacy and decrease toxicity as compared to tenofovir, ...
... LA JOLLA, Calif. , May 13 Transdel ... focused on developing topically administered products using its proprietary transdermal ... March 31, 2010 .  The Company also highlighted recent ... , ...
... , DUBLIN and PHILADELPHIA , ... ), the global specialty biopharmaceutical company,announces that its subsidiary Shire LLC has ... Delaware against Actavis Elizabeth LLC and,Actavis Inc. (collectively "Actavis") for the ... and 6,811,794,(the ,794 patent). , , ...
Cached Biology Technology:Chimerix Initiates Phase 1 Study of CMX157 2Chimerix Initiates Phase 1 Study of CMX157 3Transdel Pharmaceuticals Reports First Quarter 2010 Results 2Transdel Pharmaceuticals Reports First Quarter 2010 Results 3Transdel Pharmaceuticals Reports First Quarter 2010 Results 4Transdel Pharmaceuticals Reports First Quarter 2010 Results 5INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc. 2INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc. 3
(Date:7/10/2014)... The Marshall Institute for Interdisciplinary Research (MIIR) and ... Medicine today announced they will be partnering with ... drugs. , Under the agreement with Shanghai-based HD ... the costs and risks of discovery and development ... own any intellectual property and commercialization rights to ...
(Date:7/10/2014)... 2014 Amidst the astounding complexity of the billions ... the brain, how do nerve cells decide how far ... do they coordinate these events within the developing brain? ... campus of The Scripps Research Institute (TSRI) have shed ... particular protein plays a far more sophisticated role in ...
(Date:7/10/2014)... Ore. Nuclear engineers at Oregon State University have ... device that should help people all over the world ... intensity, and whether or not it poses a health ... to public demand following the nuclear incident in Fukushima, ... what level of radiation they were being exposed to ...
Breaking Biology News(10 mins):Marshall University to partner with international company in drug development venture 2Scripps Florida scientists shed new light on nerve cell growth 2Sophisticated radiation detector designed for broad public use 2Sophisticated radiation detector designed for broad public use 3
... research into cheetah cub survival has refuted the theory that ... cannot coexist in conservation areas. The study, published in the ... Kgalagadi Transfrontier Park were seven times more likely to survive ... found to be the cubs, main predatory threat. Previously, ...
... MA -- Researchers at MIT and Brigham and Women,s ... of intestinal stem cells, then stimulate them to develop ... intestinal cells. Using these cells, scientists could develop and ... colitis. The small intestine, like most other body ...
... approach to mapping how proteins interact with each other, ... aid in the design of new drugs for diseases ... artificial amino acids, the Salk scientists determine the detailed ... the molecule that turns it on. The switch--corticotrophin releasing ...
Cached Biology News:Researchers unlock a new means of growing intestinal stem cells 2Researchers unlock a new means of growing intestinal stem cells 3Salk scientists crack riddle of important drug target 2Salk scientists crack riddle of important drug target 3
Lentigen's manufacturing platform is sufficiently versatile for use in the manufacture of any HIV-based Lentiviral vector. Lentigen will manufacture your LV of choice to the highest possible titer a...
Applications: Epitope mapping, Mapping protein-protein contacts, Identification of enzyme substrates/inhibitors, Identification of receptor agonists/antagonists...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Request Info...
Biology Products: